0001193125-14-133398.txt : 20140519 0001193125-14-133398.hdr.sgml : 20140519 20140407151033 ACCESSION NUMBER: 0001193125-14-133398 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20140407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cerulean Pharma Inc. CENTRAL INDEX KEY: 0001401914 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 5TH FLOOR CITY: Cambridge STATE: MA ZIP: 02139 BUSINESS PHONE: 617-551-9600 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 5TH FLOOR CITY: Cambridge STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc DATE OF NAME CHANGE: 20070604 CORRESP 1 filename1.htm Company Acceleration Request

Cerulean Pharma Inc.

840 Memorial Drive

Cambridge, MA 02139

April 7, 2014

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re: Cerulean Pharma Inc.
     Registration Statement on Form S-1
     File No. 333-194442
     Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Cerulean Pharma Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-194442), as amended (the “Registration Statement”), so that it may become effective at 5:30 p.m. Eastern time on April 9, 2014, or as soon thereafter as practicable.

The Registrant hereby acknowledges that:

 

(a) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

 

(b) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

 

(c) the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

[The remainder of this page is intentionally left blank.]

Very truly yours,
Cerulean Pharma Inc.
By:  

/s/ Oliver S. Fetzer

Name:   Oliver S. Fetzer
Title:   President and Chief Executive Officer